Evidence reviewed: 22 July 2026 · Author: ExtolX Editorial Team · Scientific review: Pending
Educational information for laboratory research audiences. This article does not provide medical advice, dosage or administration guidance.
MOTS-c is a 16-amino-acid peptide encoded within mitochondrial 12S rRNA. Research explores metabolic stress signalling, but most intervention evidence remains preclinical.
Key points
- The compound is a mitochondrial-derived peptide encoded by a short open reading frame in mitochondrial DNA.
- Evidence from cells, animals and humans must be interpreted separately.
- Investigational; no MHRA-authorised MOTS-c medicine was identified.
- Research findings do not establish that independently supplied material is equivalent to a clinical-trial product.
What is it?
MOTS-c is a 16-amino-acid peptide encoded within mitochondrial 12S rRNA. Research explores metabolic stress signalling, but most intervention evidence remains preclinical. In scientific work, identity should be established through appropriate analytical documentation rather than inferred from a product name alone.
How is it thought to work?
Under metabolic stress, MOTS-c has been reported to interact with folate–AICAR–AMPK signalling and to influence nuclear gene expression. The field is still resolving where the peptide is produced, how it is measured and how circulating concentrations should be interpreted.
What does the current evidence show?
- Mouse and cell studies report effects on metabolic adaptation and skeletal-muscle homeostasis.
- A small human exercise study found a trend in circulating MOTS-c after endurance exercise, while later work raised questions about skeletal muscle as the circulating source.
- Observational studies of circulating MOTS-c in obesity and diabetes have produced inconsistent results.
Evidence snapshot
| Evidence level | What it can establish | Main caution |
|---|---|---|
| Laboratory | Biochemical activity and cellular responses under defined conditions | Does not establish effects in an intact organism |
| Animal | Mechanisms and model-specific biological responses | Translation to humans is uncertain |
| Human | Outcomes in the studied population and formulation | Must not be generalised beyond the actual trial |
What remains unknown?
- Human intervention trials of exogenous MOTS-c are lacking.
- Commercial immunoassays and sample handling may contribute to inconsistent concentration estimates.
- Associations between endogenous MOTS-c and disease do not demonstrate effects of administering synthetic peptide.
Regulatory and safety context
Investigational; no MHRA-authorised MOTS-c medicine was identified. A research-use label does not override the way a product is presented, promoted or used. Safety information from one formulation or jurisdiction cannot be transferred automatically to another.
Frequently asked questions
Does published research prove a benefit?
No. A finding must be interpreted in the context of its model, study design, population, formulation and endpoints. Preliminary or preclinical findings are not proof of clinical benefit.
Is research material equivalent to material used in a clinical trial?
Not on the basis of a shared name. Equivalence would require evidence concerning identity, manufacture, purity, formulation, stability and biological activity.
References and further reading
- Exercise and human MOTS-c — PubMed
- Age-dependent physical decline study — PubMed
- Systematic review — PubMed
Research-use notice: ExtolX products are supplied strictly for legitimate laboratory research. They are not intended for human or veterinary use, consumption, diagnosis, treatment or prevention of disease.